Press Releases
Press Releases
EU approves Astrazeneca Plc’s New Antibiotic Zavicefta
AstraZeneca announced that the EC has granted marketing authorisation for Zavicefta(ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients...
Press Releases
TECHNIDATA Joins Cercle Idéo, which unites partner companies of MC2,arts center of grenoble, france
TECHNIDATA, the software supplier for clinical laboratories and biorepositories, renews its support for the arts center of Grenoble, France, and joins Cercle Idéo, the new...
Press Releases
Sanofi, Boehringer Ingelheim agree to swap animal health, consumer healthcare businesses
Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December 2015 which consists of an exchange of Sanofi’s...
Press Releases
Daiichi Sankyo Enters Into Agreement with Servier Canada For Factor Xa Inhibitor Edoxaban
Daiichi Sankyo Co Limited announced that it has entered into an agreement with Servier Canada whereby Servier Canada will market the oral, once-daily anti-coagulant edoxaban...
Press Releases
Vital Launches Application Neutral Architecture to Deliver Advanced Interoperability and Workf
Vital Images, Inc a Minneapolis-based advanced medical imaging and informatics company, is pleased to announce the launch of the latest addition to its enterprise clinical...
Press Releases
Takeda Revises Collaboration Agreement with Amgen to Returns Certain Molecules, Products
Takeda Pharmaceutical Company Limited announced revisions on an existing collaboration agreement, under which Takeda had rights to develop and commercialize multiple molecules / products from...
Press Releases
EC grants marketing authorisation to Odefsey in HIV
Gilead Sciences, Inc announced that the EC hs granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey®(emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
